Welcome to our dedicated page for Vertex Pharmaceuticals news (Ticker: VRTX), a resource for investors and traders seeking the latest updates and insights on Vertex Pharmaceuticals stock.
Vertex Pharmaceuticals Inc (VRTX) is a global biopharmaceutical leader focused on transformative therapies for serious diseases. This page serves as the definitive source for all official Vertex news, including regulatory milestones, clinical developments, and strategic partnerships.
Investors and researchers will find timely updates on cystic fibrosis treatment advancements, gene-editing therapy progress, and pipeline expansions into pain management and blood disorders. Our curated feed includes earnings announcements, FDA submissions, and peer-reviewed research publications.
The repository features three core categories: Treatment Approvals (new drug applications and label expansions), Research Breakthroughs (clinical trial results and preclinical discoveries), and Strategic Developments (collaborations and manufacturing updates). Each entry provides direct access to primary source materials.
For ongoing monitoring of Vertex's innovations in small-molecule drugs and CRISPR-based therapies, bookmark this page or check back regularly. All content is vetted against original company disclosures to ensure regulatory compliance and factual accuracy.
Vertex Pharmaceuticals (Nasdaq: VRTX) announced that Paul Negulescu, Ph.D., Senior Vice President, has been awarded the prestigious 2025 Canada Gairdner International Award for his groundbreaking research in cystic fibrosis (CF). The award recognizes his pioneering work in understanding CF's cellular and molecular mechanisms, leading to transformative drug therapies.
Under Negulescu's leadership, Vertex developed the first-ever protein folding corrector medicines that treat CF's underlying cause. The company's most recent achievement is a triple combination therapy that can treat over 90% of CF patients with more than 300 different mutations through once-daily dosing.
Vertex currently has five approved CF medicines that restore function of the defective CFTR protein. The research team continues to develop new therapies, including an mRNA approach in clinical development, targeting the remaining 10% of patients who don't respond to existing treatments.
Vertex Pharmaceuticals (Nasdaq: VRTX) has scheduled its first quarter 2025 financial results announcement for Monday, May 5, 2025, after market close. The company will host a conference call and webcast at 4:30 p.m. ET to discuss the results.
Investors can access the call by dialing (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and referencing the 'Vertex Pharmaceuticals First Quarter 2025 Earnings Call.' A live webcast will be available through the Investors section of Vertex's website at www.vrtx.com. Participants are advised to register 15 minutes before the scheduled webcast to ensure timely connection. An archived version of the webcast will be available on the company's website.
Vertex Pharmaceuticals (VRTX) has received European Commission approval for an expanded label of KAFTRIO® in combination with ivacaftor for treating cystic fibrosis (CF). The expansion covers patients aged 2 years and older with at least one non-class I mutation in the CFTR gene.
This regulatory approval makes approximately 4,000 additional people in the European Union eligible for this treatment that addresses the underlying cause of their disease. Several countries including Austria, Denmark, Ireland, Norway, Sweden, and Germany will provide immediate access to eligible patients through existing reimbursement agreements.
Vertex Pharmaceuticals (VRTX) has announced significant updates to its Type 1 diabetes (T1D) portfolio. The company reported that while VX-264, their encapsulated pancreatic islet cell therapy, was safe and well-tolerated, it failed to meet efficacy endpoints and will not advance further in clinical trials.
On a positive note, zimislecel (formerly VX-880), their fully differentiated islet cell therapy, is progressing well in Phase 3 trials. The pivotal trial is expected to complete enrollment and dosing in H1 2025, with global regulatory submissions planned for 2026. If approved, zimislecel could benefit approximately 60,000 people with severe T1D across the U.S. and Europe.
The company continues to pursue research-stage T1D programs, including alternative immunosuppressive regimens, gene-edited hypoimmune stem-cell derived islet cell therapies, and novel encapsulation devices.
Vertex Pharmaceuticals (VRTX) has received UK MHRA approval for ALYFTREK®, a once-daily triple combination CFTR modulator therapy for cystic fibrosis treatment. The medication is approved for patients 6 years and older with at least one F508del mutation or another responsive mutation in the CFTR gene.
In head-to-head clinical trials, ALYFTREK demonstrated non-inferior ppFEV1 results and improved sweat chloride levels compared to existing treatments. This marks Vertex's fifth CFTR modulator regimen, offering a more flexible and less burdensome treatment option.
The company is currently working with NICE and NHS to ensure patient access in the UK. ALYFTREK received FDA approval in December 2024, with additional regulatory applications pending in Europe, Canada, Switzerland, Australia, and New Zealand.
Vertex Pharmaceuticals (VRTX) received a positive opinion from the European Medicines Agency's CHMP for expanding the label of KAFTRIO® in combination with ivacaftor. The expansion would cover the treatment of cystic fibrosis (CF) patients aged 2 years and older who have at least one non-class I mutation in the CFTR gene.
If approved, this expansion would make approximately 4,000 additional patients in the European Union eligible for CFTR modulator treatment that addresses the underlying cause of their disease. Currently, KAFTRIO is approved in the EU for CF patients aged 2 years and older with at least one copy of the F508del mutation in the CFTR gene.
Vertex Pharmaceuticals (VRTX) has announced its participation in three major investor conferences in March 2025. Stuart Arbuckle, EVP and COO, and David Altshuler, EVP of Global Research and CSO, will join a fireside chat at the TD Cowen 45th Annual Health Care Conference on March 3 at 3:10 p.m. ET.
Charles Wagner, EVP and CFO, along with Dr. Altshuler, will participate in the 2025 Leerink Partners Global Healthcare Conference on March 10 at 10:00 a.m. ET. Additionally, Susie Lisa, SVP of Investor Relations, and Miroslava Minkova, Executive Director of IR, will attend the Jefferies Biotech on the Beach Summit on March 11.
Live webcasts of management presentations will be accessible through the company's website at www.vrtx.com under the Investors section, with replays available afterward.
Vertex Pharmaceuticals reported strong financial results for Q4 and full year 2024, with full-year product revenue reaching $11.02 billion, a 12% increase from 2023. The company provided 2025 revenue guidance of $11.75 to $12.0 billion.
Key highlights include FDA approvals for ALYFTREK for cystic fibrosis patients ages 6+ and JOURNAVX for moderate-to-severe acute pain. Q4 2024 product revenue increased 16% to $2.91 billion, with U.S. revenue up 17% to $1.84 billion and international revenue up 14% to $1.07 billion.
The company announced leadership changes, with COO Stuart Arbuckle retiring July 1, 2025. CFO Charlie Wagner will assume the additional role of COO, while Duncan McKechnie will become CCO. Cash position stood at $11.2 billion as of December 31, 2024, down from $13.7 billion year-over-year due to the Alpine acquisition and share repurchases.
Vertex Pharmaceuticals (VRTX) has secured a reimbursement agreement with NHS England for CASGEVY®, its CRISPR/Cas9 gene-edited therapy, for eligible sickle cell disease (SCD) patients. This follows the National Institute for Health and Care Excellence (NICE) issuing positive guidance recommending CASGEVY's use in the NHS.
The agreement expands upon a previous reimbursement deal reached in August 2024 for transfusion-dependent beta thalassemia (TDT) patients. Vertex is working to establish a network of independently operated authorized treatment centers (ATCs) throughout England, as the therapy requires specialized experience in stem cell transplantation and hemoglobinopathy management.
Vertex Pharmaceuticals (NASDAQ: VRTX) has received FDA approval for JOURNAVX™ (suzetrigine), marking a significant breakthrough in pain management. The drug is the first non-opioid oral pain signal inhibitor and the first new pain medicine class approved in over 20 years.
JOURNAVX is specifically designed for treating adults with moderate-to-severe acute pain. As a highly selective NaV1.8 pain signal inhibitor, it offers effective pain relief with a favorable safety profile and no evidence of addictive potential. This development is particularly significant for the approximately 80 million Americans who receive prescriptions for moderate-to-severe acute pain annually.
The company has established patient support programs to facilitate access to JOURNAVX for qualified patients, with more information available at JOURNAVX.com.
